β`χΰαι 20 ξ"β
|
|
ων δϊψετδ αΰπβμιϊ: Jakavi 20 Mg.
ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
|
|
 αρμ δαψιΰεϊ
φεψϊ ξϊο
PER OS
ξιπεο
Tablets
ωιξεω αϊψετδ
Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ξρτψ ψιωεν
149 87 33750 00
ιφψο
Novartis Pharma Stein Ag, Switzerland
ϊεχσ ψιωιεο μϊψετδ
05/2013 - 04/2018
|
ηεξψ τςιμ
|
ψιλεζ / λξεϊ αιηιγϊ ξιπεο
|
| Ruxolitinib as phosphate |
20 MG |
|
ΰψιζδ
|
λξεϊ αΰψιζδ
|
ηιι ξγσ
|
ϊψετϊ ξψων
|
| Blister pvc/pctfe |
56 x TABLETS |
ηεγωιν 24 |
λο |
| Bottle hdpe |
60 x TABLETS |
ηεγωιν 24 |
λο |
|
|
|
|
